Dewpoint drives drug discovery though a proprietary end-to-end experimental and AI-powered platform.
As of Q1 2023, the company has programs across an varied pipeline spanning oncology, neurodegenerative, cardiopulmonary, and metabolic disease indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer and Novo Nordisk.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze